SG187513A1 - Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof - Google Patents
Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof Download PDFInfo
- Publication number
- SG187513A1 SG187513A1 SG2013005624A SG2013005624A SG187513A1 SG 187513 A1 SG187513 A1 SG 187513A1 SG 2013005624 A SG2013005624 A SG 2013005624A SG 2013005624 A SG2013005624 A SG 2013005624A SG 187513 A1 SG187513 A1 SG 187513A1
- Authority
- SG
- Singapore
- Prior art keywords
- veev
- alphavirus
- ires
- virus
- cells
- Prior art date
Links
- 241000710929 Alphavirus Species 0.000 title claims abstract description 73
- 241000255925 Diptera Species 0.000 title claims abstract description 61
- 230000002238 attenuated effect Effects 0.000 title claims abstract description 46
- 230000003362 replicative effect Effects 0.000 title claims abstract description 23
- 241000700605 Viruses Species 0.000 claims abstract description 74
- 238000000034 method Methods 0.000 claims abstract description 37
- 239000013598 vector Substances 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 230000002163 immunogen Effects 0.000 claims abstract description 11
- 230000005540 biological transmission Effects 0.000 claims abstract description 7
- 241001502567 Chikungunya virus Species 0.000 claims abstract description 4
- 241000710945 Eastern equine encephalitis virus Species 0.000 claims abstract description 3
- 241000710951 Western equine encephalitis virus Species 0.000 claims abstract 2
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 143
- 210000004027 cell Anatomy 0.000 claims description 93
- 230000035772 mutation Effects 0.000 claims description 66
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 48
- 208000015181 infectious disease Diseases 0.000 claims description 30
- 241000710188 Encephalomyocarditis virus Species 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 101800000980 Protease nsP2 Proteins 0.000 claims description 19
- 230000003044 adaptive effect Effects 0.000 claims description 17
- 230000029812 viral genome replication Effects 0.000 claims description 15
- 230000001419 dependent effect Effects 0.000 claims description 14
- 210000000234 capsid Anatomy 0.000 claims description 9
- 230000037430 deletion Effects 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 8
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 7
- 238000010367 cloning Methods 0.000 claims description 7
- 230000012010 growth Effects 0.000 claims description 7
- 108091026890 Coding region Proteins 0.000 claims description 6
- 210000003705 ribosome Anatomy 0.000 claims description 6
- 230000002950 deficient Effects 0.000 claims description 5
- 230000011664 signaling Effects 0.000 claims description 5
- 101710159910 Movement protein Proteins 0.000 claims description 4
- 101710144117 Non-structural protein 4 Proteins 0.000 claims description 4
- 101800001758 RNA-directed RNA polymerase nsP4 Proteins 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 108090000565 Capsid Proteins Proteins 0.000 claims description 3
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 3
- 101710121417 Envelope glycoprotein Proteins 0.000 claims description 3
- 101710091045 Envelope protein Proteins 0.000 claims description 3
- 101710144128 Non-structural protein 2 Proteins 0.000 claims description 3
- 101710199667 Nuclear export protein Proteins 0.000 claims description 3
- 101710188315 Protein X Proteins 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 244000144972 livestock Species 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000011144 upstream manufacturing Methods 0.000 claims description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 abstract description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 50
- 230000010076 replication Effects 0.000 description 42
- 230000003612 virological effect Effects 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 22
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 17
- 238000001890 transfection Methods 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 239000012634 fragment Substances 0.000 description 13
- 230000002458 infectious effect Effects 0.000 description 13
- 229960005486 vaccine Drugs 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 10
- 230000014616 translation Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 101710172711 Structural protein Proteins 0.000 description 8
- 108010087302 Viral Structural Proteins Proteins 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 235000021186 dishes Nutrition 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 108020003589 5' Untranslated Regions Proteins 0.000 description 6
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 108010047761 Interferon-alpha Proteins 0.000 description 5
- 102000006992 Interferon-alpha Human genes 0.000 description 5
- 108020000999 Viral RNA Proteins 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 5
- 230000008092 positive effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000003501 vero cell Anatomy 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 241000238421 Arthropoda Species 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000006819 RNA synthesis Effects 0.000 description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 description 3
- 206010058874 Viraemia Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000000531 effect on virus Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000007758 minimum essential medium Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 3
- 229940045145 uridine Drugs 0.000 description 3
- 230000009447 viral pathogenesis Effects 0.000 description 3
- 241000256118 Aedes aegypti Species 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 239000005996 Blood meal Substances 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 108090000944 RNA Helicases Proteins 0.000 description 2
- 102000004409 RNA Helicases Human genes 0.000 description 2
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 2
- 101150006932 RTN1 gene Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 244000037640 animal pathogen Species 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 244000052637 human pathogen Species 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 108020005096 28S Ribosomal RNA Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000710127 Cricket paralysis virus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010027814 HSP72 Heat-Shock Proteins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026750 acute meningoencephalitis Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000004209 confusion Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 206010013395 disorientation Diseases 0.000 description 1
- 230000002681 effect on RNA Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000001712 encephalitogenic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 231100000822 oral exposure Toxicity 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000012107 replication analysis Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007444 viral RNA synthesis Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6222908P | 2008-01-24 | 2008-01-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG187513A1 true SG187513A1 (en) | 2013-02-28 |
Family
ID=41217313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013005624A SG187513A1 (en) | 2008-01-24 | 2009-01-23 | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof |
| SG10201606111XA SG10201606111XA (en) | 2008-01-24 | 2009-01-23 | Attenuated Recombinant Alphaviruses Incapable Of Replicating In Mosquitoes And Uses Thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201606111XA SG10201606111XA (en) | 2008-01-24 | 2009-01-23 | Attenuated Recombinant Alphaviruses Incapable Of Replicating In Mosquitoes And Uses Thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8426188B2 (enExample) |
| EP (2) | EP2250269B1 (enExample) |
| JP (1) | JP5758632B2 (enExample) |
| KR (2) | KR101913790B1 (enExample) |
| CN (1) | CN102083986B (enExample) |
| AU (1) | AU2009238667A1 (enExample) |
| CA (2) | CA2910235C (enExample) |
| CO (1) | CO6290702A2 (enExample) |
| IL (2) | IL207167A (enExample) |
| MX (3) | MX378503B (enExample) |
| MY (1) | MY178870A (enExample) |
| NZ (2) | NZ603790A (enExample) |
| SG (2) | SG187513A1 (enExample) |
| WO (1) | WO2009131604A2 (enExample) |
| ZA (1) | ZA201005943B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2947149T3 (pl) * | 2007-06-21 | 2018-09-28 | Alphavax, Inc. | Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych |
| CA2910235C (en) | 2008-01-24 | 2021-07-06 | Scott C. Weaver | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof |
| US8961995B2 (en) | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
| US9701719B2 (en) | 2012-09-27 | 2017-07-11 | Research Development Foundation | Attenuated Chikungunya virus |
| BR112015023205A2 (pt) | 2013-03-14 | 2017-07-18 | Takeda Vaccines Inc | composições e métodos para formulações de alfavírus vivo atenuado |
| EP3436062A1 (en) * | 2016-03-31 | 2019-02-06 | Takeda Vaccines, Inc. | Live, attenuated alphavirus constructs and methods and uses thereof |
| BR112018074277A2 (pt) * | 2016-05-27 | 2019-10-01 | Griffith University | vacina de alfavírus artrogênica |
| JP2020518648A (ja) | 2017-05-08 | 2020-06-25 | グリットストーン オンコロジー インコーポレイテッド | アルファウイルス新生抗原ベクター |
| WO2020028749A1 (en) * | 2018-08-03 | 2020-02-06 | Uab Research Foundation | Methods and compositions for alphavirus vaccine |
| CN109536464B (zh) * | 2018-12-10 | 2022-06-10 | 中国科学院武汉病毒研究所 | 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用 |
| AU2020282369A1 (en) | 2019-05-30 | 2022-01-20 | Seattle Project Corp. | Modified adenoviruses |
| CA3162690A1 (en) | 2019-12-31 | 2021-07-08 | Minoru S. H. Ko | Temperature-based transient delivery of nucleic acids and proteins to cells and tissues |
| WO2022032196A2 (en) | 2020-08-06 | 2022-02-10 | Gritstone Bio, Inc. | Multiepitope vaccine cassettes |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451592B1 (en) * | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| CA2327189A1 (en) * | 2000-12-21 | 2002-06-21 | The Minister Of National Defence | Novel dna-based vaccine against the encephalitis alphaviruses |
| JP5016305B2 (ja) * | 2003-03-20 | 2012-09-05 | アルファヴァックス，インコーポレイテッド | 改良されたアルファウイルスレプリコンおよびヘルパー構築物 |
| CA2533614C (en) | 2004-07-30 | 2011-05-03 | Research In Motion Limited | Method and system for coordinating device setting between a communications client and its host device |
| US7332322B2 (en) * | 2004-09-14 | 2008-02-19 | Ilya Frolov | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof |
| CA2579507C (en) | 2006-03-15 | 2017-06-13 | Institut Pasteur | Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof |
| CA2910235C (en) * | 2008-01-24 | 2021-07-06 | Scott C. Weaver | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof |
-
2009
- 2009-01-23 CA CA2910235A patent/CA2910235C/en not_active Expired - Fee Related
- 2009-01-23 JP JP2010544350A patent/JP5758632B2/ja not_active Expired - Fee Related
- 2009-01-23 CA CA2713165A patent/CA2713165C/en not_active Expired - Fee Related
- 2009-01-23 MY MYPI2010003463A patent/MY178870A/en unknown
- 2009-01-23 SG SG2013005624A patent/SG187513A1/en unknown
- 2009-01-23 EP EP09735287.6A patent/EP2250269B1/en not_active Not-in-force
- 2009-01-23 MX MX2019010530A patent/MX378503B/es unknown
- 2009-01-23 KR KR1020167029024A patent/KR101913790B1/ko not_active Expired - Fee Related
- 2009-01-23 SG SG10201606111XA patent/SG10201606111XA/en unknown
- 2009-01-23 NZ NZ603790A patent/NZ603790A/en not_active IP Right Cessation
- 2009-01-23 AU AU2009238667A patent/AU2009238667A1/en not_active Abandoned
- 2009-01-23 CN CN200980110510.1A patent/CN102083986B/zh not_active Expired - Fee Related
- 2009-01-23 KR KR1020107018777A patent/KR101668849B1/ko not_active Expired - Fee Related
- 2009-01-23 MX MX2014010258A patent/MX367792B/es unknown
- 2009-01-23 EP EP16000617.7A patent/EP3085787B1/en not_active Not-in-force
- 2009-01-23 WO PCT/US2009/000458 patent/WO2009131604A2/en not_active Ceased
- 2009-01-23 MX MX2010007989A patent/MX2010007989A/es active IP Right Grant
- 2009-01-23 NZ NZ587502A patent/NZ587502A/xx not_active IP Right Cessation
-
2010
- 2010-07-22 IL IL207167A patent/IL207167A/en active IP Right Grant
- 2010-07-23 US US12/804,535 patent/US8426188B2/en active Active
- 2010-08-20 ZA ZA2010/05943A patent/ZA201005943B/en unknown
- 2010-08-20 CO CO10102866A patent/CO6290702A2/es active IP Right Grant
-
2013
- 2013-04-03 US US13/855,960 patent/US9580690B2/en active Active
-
2014
- 2014-04-09 IL IL232032A patent/IL232032A0/en unknown
-
2017
- 2017-02-27 US US15/443,364 patent/US10533186B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10533186B2 (en) | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof | |
| Paessler et al. | Recombinant sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic | |
| Aréchiga-Ceballos et al. | Alphaviral equine encephalomyelitis (Eastern, Western and Venezuelan) | |
| Vander Veen et al. | Alphavirus replicon vaccines | |
| Erasmus et al. | Novel insect-specific eilat virus-based chimeric vaccine candidates provide durable, mono-and multivalent, single-dose protection against lethal alphavirus challenge | |
| Volkova et al. | IRES-dependent replication of Venezuelan equine encephalitis virus makes it highly attenuated and incapable of replicating in mosquito cells | |
| KR20090008193A (ko) | 가감염성 플라비바이러스 및 이들의 용도 | |
| US20190106682A1 (en) | Live, Attenuated Alphavirus Constructs and Methods and Uses Thereof | |
| US8343506B2 (en) | Chimeric chikungunya virus and uses thereof | |
| US9402890B2 (en) | Methods and compositions for pseudoinfectious alphaviruses | |
| Ryman et al. | Attenuation of Sindbis virus variants incorporating uncleaved PE2 glycoprotein is correlated with attachment to cell-surface heparan sulfate | |
| AU2018229512B2 (en) | Attentuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof | |
| AU2014265084B2 (en) | Attentuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof | |
| HK1230647A1 (en) | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof | |
| Attenuated | Recombinant Sindbis/Venezuelan Equine | |
| Vander Veen et al. | A manuscript submitted to Animal Health Research Reviews |